Biodesix/BDSX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Biodesix

Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Ticker

BDSX

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

Headquarters

Boulder, United States

Employees

217

Biodesix Metrics

BasicAdvanced
$164M
Market cap
-
P/E ratio
-$0.55
EPS
1.18
Beta
-
Dividend rate
$164M
1.18
$2.21
$1.03
2.9
0.912
-3.71%
-56.02%
-82.08%
2.99
34.70%
59.09%
2.52%

What the Analysts think about Biodesix

Analyst Ratings

Majority rating from 4 analysts.
Buy

Biodesix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-91.89% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$15M
1.37%
Net income
-$14M
49.45%
Profit margin
-91.89%
47.45%

Biodesix Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.33%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.17
-$0.14
-$0.10
-$0.14
-
Expected
-$0.21
-$0.15
-$0.11
-$0.14
-$0.09
Surprise
-17.74%
-6.67%
-9.09%
-2.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Biodesix stock?

Biodesix (BDSX) has a market cap of $164M as of June 25, 2024.

What is the P/E ratio for Biodesix stock?

The price to earnings (P/E) ratio for Biodesix (BDSX) stock is 0 as of June 25, 2024.

Does Biodesix stock pay dividends?

No, Biodesix (BDSX) stock does not pay dividends to its shareholders as of June 25, 2024.

When is the next Biodesix dividend payment date?

Biodesix (BDSX) stock does not pay dividends to its shareholders.

What is the beta indicator for Biodesix?

Biodesix (BDSX) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Biodesix stock price target?

The target price for Biodesix (BDSX) stock is $3.1, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Biodesix stock

Buy or sell Biodesix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing